Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1148/radiol.250215 | DOI Listing |
Front Public Health
March 2025
Department of Radiological Intervention, Tianjin First Central Hospital, Nankai District, Tianjin, China.
Objective: The study aims to establish a reliable method for reducing radiation dose by analyzing variations in radiation dose from digital subtraction machines (DSA).
Methods: The study investigates changes in bed plate height (80-110 cm), detection height (0-30 cm), visual field size (6 × 6 inches and 12 × 12 inches), and radiation doses affecting various body parts, including the lens, thyroid, chest, gonads, and lower limbs. Radiation doses were measured using Raysafe X2 dosimetry for patients and AT1123 meter for operators.
Invest Radiol
March 2025
From the Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland (B.K., F.E., J.K., R.H., C.B., M.M., T.F., L.J.); Advanced Radiology Center, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy (C.S., A.R.L.); and Section of Radiology, Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore Rome, Italy (A.R.L.).
Objectives: The aim of the study was to evaluate the effect of photon-counting detector (PCD-)CT dose reduction to x-ray equivalent levels on nodule detection, diameter, volume, and density compared to a low-dose reference standard using semiautomated and manual methods.
Materials And Methods: Between February and July 2023, 101 prospectively enrolled participants underwent noncontrast same-study low- and chest x-ray-dose CT scans using PCD-CT. Patients who were not referred for lung cancer screening or nodule follow-up, as well as those with nodules smaller than 5 mm in diameter, were excluded.
Zhonghua Jie He He Hu Xi Za Zhi
March 2025
Bronchial asthma (asthma) is a common chronic respiratory disease. Standardized diagnosis, treatment and effective clinical management are critical to improving asthma control, improving patients' quality of life, and reducing the disease burden. Based on the latest evidence-based research from both domestic and international references, the Asthma Group of the Chinese Thoracic Society has revised the " ()".
View Article and Find Full Text PDFJAMA Otolaryngol Head Neck Surg
March 2025
Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.
Importance: Patients with head and neck squamous cell cancer (HNSCC) are at a greater risk of developing pulmonary metastases and/or second primary lung cancer. However, it remains uncertain whether lung screening in these patients, when the initial staging studies are negative, confers any survival benefit.
Objective: To evaluate long-term cancer survival outcomes in patients with HNSCC undergoing chest radiography vs low-dose computed tomography screening for pulmonary metastasis and/or second primary lung cancer.
PLoS One
March 2025
Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, Athens, Greece.
Objective: This study aimed to assess the cost-effectiveness of lung cancer screening (LCS) employing volume-based low-dose computed tomography (LDCT) in contrast to the absence of screening, targeting an asymptomatic high-risk population in Greece, leveraging the outcomes derived from the NELSON study, the largest European randomized control trial dedicated to LCS.
Methods: A validated model incorporating a decision tree and an integrated state-transition Markov model was used to simulate the identification, diagnosis, and treatments for a population at high risk of developing lung cancer, from a healthcare payer perspective. Screen-detected lung cancers, costs, life years (LYs), quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) were predicted.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!